DBV Technologies (DBVT) Operating Leases (2019 - 2026)
DBV Technologies (DBVT) posted Operating Leases of $7.7 million for Q2 2026, up 26.23% sequentially from $6.1 million in Q1 2026, and little changed YoY from $7.7 million in Q2 2025.
DBV Technologies (DBVT) Operating Leases (2019 - 2026) Analysis & Trends
DBV Technologies has reported Operating Leases for 8 years, with the latest figure at $7.7 million in Q2 2026.
- Quarterly Operating Leases changed 0.06% year-over-year to $7.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.7 million (changed 0.06% YoY) and the FY2025 annual result came in at $6.5 million, down 6.49% from the prior year.
- Operating Leases climbed to $7.7 million in Q2 2026 per DBVT's latest filing, from $6.1 million in the prior quarter.
- Over five years, Operating Leases peaked at $7.7 million in Q2 2026 and troughed at $1.6 million in Q3 2023.
- A 5-year average of $5.4 million and a median of $6.3 million in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2024: Operating Leases tumbled 70.24% in 2022, then soared 358.66% in 2024.
- Over 5 years, Operating Leases stood at $3.0 million in 2022, then surged by 87.65% to $5.7 million in 2023, then gained by 22.61% to $7.0 million in 2024, then retreated by 6.49% to $6.5 million in 2025, then advanced by 18.46% to $7.7 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $7.7 million, $6.1 million, and $6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.70 Mn |
| Mar 31, 2026 | 6.10 Mn |
| Dec 31, 2025 | 6.50 Mn |
| Sep 30, 2025 | 7.69 Mn |
| Jun 30, 2025 | 7.70 Mn |
| Mar 31, 2025 | 7.23 Mn |
| Dec 31, 2024 | 6.95 Mn |
| Sep 30, 2024 | 7.41 Mn |
| Jun 30, 2024 | 7.16 Mn |
| Mar 31, 2024 | 7.03 Mn |
| Dec 31, 2023 | 5.67 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 2.60 Mn |
| Dec 31, 2022 | 3.02 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 3.94 Mn |
| Mar 31, 2022 | 4.30 Mn |
| Dec 31, 2021 | 10.15 Mn |
| Sep 30, 2021 | 8.30 Mn |